Researchers used AI to identify a new biomarker of chronic stress visible on standard CT scans by measuring adrenal gland size, which correlates with stress levels and predicts cardiovascular risk, offering a practical tool for assessing long-term stress effects in clinical settings.
A study from UNSW Sydney provides strong evidence that hearing voices in schizophrenia may be due to the brain's failure to recognize its own inner speech, with potential implications for early diagnosis and treatment of psychosis.
Scientists in the UK have developed a blood test analyzing epigenetic changes in immune cells that could potentially diagnose chronic fatigue syndrome (ME/CFS), offering hope for earlier and more accurate diagnosis, though further research is needed due to the small study size.
Scientists have identified that the protein TSPO, indicating brain inflammation, appears in specific brain regions at the same time as early amyloid-beta plaque formation in Alzheimer's disease, potentially enabling earlier diagnosis and intervention, with findings confirmed in both mouse models and human tissue.
Canadian researchers have discovered a microRNA, miR-423-5p, that can protect kidney blood vessels after injury and serve as a blood-based biomarker for early detection and treatment of chronic kidney disease, with potential applications in transplantation and other vascular-related conditions.
Research suggests that routine eye exams could detect early signs of Alzheimer's disease by identifying abnormal retinal blood vessel changes linked to genetic risk factors, potentially decades before symptoms appear, highlighting the retina's role as a window into brain health.
A recent study reveals that both newborns and Alzheimer's patients have elevated levels of the brain protein p-tau217, which plays different roles in each group—supporting healthy brain development in infants and indicating neurodegeneration in Alzheimer's. The findings suggest that understanding how the healthy brain manages tau could lead to new treatments for Alzheimer's disease.
A study suggests that a parasitic, egg-eating worm found on female blue crabs in Chesapeake Bay could serve as a biomarker for their reproductive history, helping to manage and potentially rebuild crab populations by identifying spawning females and understanding reproductive patterns, especially in low-salinity conditions.
A study found that newborns and Alzheimer's patients both have elevated levels of the biomarker p-tau217, but in newborns, this protein supports healthy brain development, whereas in Alzheimer's it is associated with disease progression. The findings suggest potential pathways for new treatments by understanding how the healthy brain regulates tau protein.
The article explores the evolving understanding of ADHD, questioning traditional diagnosis and treatment methods, highlighting the lack of clear biological markers, and emphasizing the importance of environmental and personal factors in managing the condition.
A recent study challenges the idea that taurine levels decline with age or serve as a reliable biomarker for aging, showing that taurine levels generally stay stable or increase across adulthood, and emphasizing the need for further research before considering taurine supplements as anti-aging treatments.
A recent study by the NIH found no evidence that taurine levels decline with age in humans, mice, or monkeys, challenging the idea that taurine supplements can promote healthy aging. While earlier animal studies suggested potential benefits, the new research indicates taurine is unlikely to be a reliable biomarker for aging, and more clinical trials are needed before recommending supplementation for age-related health improvements.
Scientists in South Korea have developed an AI model that predicts ADHD with 96% accuracy by analyzing retinal images, identifying key differences in blood vessels and optic discs, which could lead to faster, noninvasive diagnosis, though further research is needed with larger, more diverse samples.
Researchers have developed an AI tool that predicts which men with prostate cancer will benefit from the drug abiraterone, potentially expanding its use and enabling more personalized treatment plans, thereby improving outcomes and reducing unnecessary side effects.
Canadian researchers have identified microRNA miR-423-5p as a promising biomarker for assessing microvascular health in the kidneys, which could lead to earlier diagnosis and targeted treatments for chronic renal failure and other diseases involving small blood vessel loss.